Description
Zongertinib is a targeted therapy compound designed to inhibit HER2 signaling in colorectal cancer patients with HER2 alterations. This agent is being developed for use both as monotherapy and in combination with other treatments for HER2-positive colorectal malignancies. Based on early-phase clinical trial data, zongertinib represents a novel approach to targeting HER2-driven colorectal cancers, which represent a small but important subset of CRC cases.
Mechanism of Action
Zongertinib functions as a HER2 inhibitor, blocking the human epidermal growth factor receptor 2 protein that can drive tumor growth and proliferation when overexpressed or mutated. By targeting HER2 signaling pathways, the drug aims to disrupt cancer cell survival and growth signals that are critical for tumor progression in HER2-altered colorectal cancers.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Targeted Therapy |
 Status | Experimental |
| Administration | Oral |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.